{"id":"W4415388021","doi":"10.1002/mds.70090","title":"Feasibility of Simon Two‐Stage Futility Trials in People with Early, Symptomatically Treated Parkinson's Disease","year":2025,"lang":"en","type":"article","venue":"Movement Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Ottawa; Ottawa Hospital; Toronto Western Hospital; University of Toronto; University of Calgary","funders":"Cilag; Sanofi Genzyme; Genentech; Mitsubishi Tanabe Pharma Corporation; Alexion Pharmaceuticals; University of Toronto; Amgen; Horizon Pharmaceuticals; Parkinson Canada; Sanofi; GW Pharmaceuticals; Regeneron Pharmaceuticals; Fondation Brain Canada; University of Ottawa; Krembil Foundation; University of Pennsylvania; Canadian Institutes of Health Research; Prothena; Neuraxpharm; Teva Pharmaceutical Industries; AveXis; International Parkinson and Movement Disorder Society; Biogen; PTC Therapeutics; Celgene; CHDI Foundation; CSL Behring; Bristol-Myers Squibb; Michael J. Fox Foundation for Parkinson's Research","keywords":"Clinical trial; Movement disorders; Disease; MEDLINE; Outcome (game theory); Drug trial","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1707593,0.001359288,0.002075336,0.001121852,0.001040801,0.001987389,0.001141349,0.001978271,0.005424651],"category_scores_gemma":[0.1785852,0.0007037206,0.004178818,0.00111374,0.001574743,0.002786479,0.002313743,0.001512922,0.0007013174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001350792,"about_ca_system_score_gemma":0.004151005,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007948384,"about_ca_topic_score_gemma":0.001654085,"domain_scores_codex":[0.849686,0.1359671,0.004774133,0.003985114,0.003908177,0.001679336],"domain_scores_gemma":[0.7766612,0.1710793,0.02855662,0.01211136,0.008104649,0.00348686],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5133011,0.004784305,0.2142531,0.003867987,0.008116008,0.0003622453,0.002042822,0.02060771,0.00280872,0.006975141,0.006595902,0.2162849],"study_design_scores_gemma":[0.1426063,0.3388617,0.3603671,0.002524232,0.008654778,0.00113889,0.001240971,0.07700735,0.005935174,0.02557175,0.03534158,0.0007501449],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9393985,0.005137677,0.02715864,0.003241674,0.0003595104,0.0147073,0.00405985,0.000327879,0.00560896],"genre_scores_gemma":[0.9641666,0.0004288886,0.01791764,0.0006596558,0.0001313186,0.01432722,0.001645413,0.00003095292,0.0006922743],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1707593,"threshold_uncertainty_score":0.9030725,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02190746404161951,"score_gpt":0.3118975468708066,"score_spread":0.289990082829187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}